UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3499-3506

2012

Volltextzugriff (PDF)

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer―Results from NCIC CTG/AGITG CO.17

Clinical cancer research, 2014-02, Vol.20 (3), p.744-753

2014

Volltextzugriff (PDF)

Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy

Journal of clinical oncology, 2007-03, Vol.25 (9), p.1099-1106

2007

Volltextzugriff (PDF)

Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4089-4095

2009

Volltextzugriff (PDF)

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

European journal of cancer (1990), 2014-01, Vol.50 (2), p.320-331

2014

Volltextzugriff (PDF)

Reply to E.C. Harrold et al and A.O. Ayoola et al

Journal of clinical oncology, 2016-12, Vol.34 (34), p.4194-4195

2016

Volltextzugriff (PDF)

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3191-3198

2010

Volltextzugriff (PDF)

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

Journal of geriatric oncology, 2018-01, Vol.9 (1), p.32-39

2018

Volltextzugriff (PDF)

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study

BMC cancer, 2014-12, Vol.14 (1), p.897-897, Article 897

2014

Volltextzugriff (PDF)

Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma

BMC cancer, 2015-10, Vol.15 (1), p.802, Article 802

2015

Volltextzugriff (PDF)

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919

2015

Volltextzugriff (PDF)

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

European journal of cancer (1990), 2015-01, Vol.51 (1), p.18-26

2015

Volltextzugriff (PDF)

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

The lancet oncology, 2017-09, Vol.18 (9), p.1159-1171

2017

Volltextzugriff (PDF)

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

Clinical colorectal cancer, 2018-12, Vol.17 (4), p.313-319

2018

Volltextzugriff (PDF)

Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis

European journal of cancer (1990), 2011-08, Vol.47 (12), p.1826-1836

2011

Volltextzugriff (PDF)

Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]

European journal of cancer (1990), 2012-02, Vol.48 (3), p.407-407

2012

Volltextzugriff (PDF)

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

Clinical colorectal cancer, 2018-12, Vol.17 (4), p.e617-e629

2018

Volltextzugriff (PDF)

Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3564-3564

2023

Volltextzugriff (PDF)

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

JNCI : Journal of the National Cancer Institute, 2009-09, Vol.101 (17), p.1182-1192

2009

Volltextzugriff (PDF)

A prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT in vitro diagnostic for the detection of biomarkers associated with colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3529-3529

2023

Volltextzugriff (PDF)

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine―oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

British journal of cancer, 2012-01, Vol.106 (1), p.61-69

2012

Volltextzugriff (PDF)

Oxaliplatin‐induced interstitial lung disease

Asia-Pacific journal of clinical oncology, 2008-09, Vol.4 (3), p.175-180

2008

Volltextzugriff (PDF)

SIRFLOX study: Novel approach to define depth of response (DpR) within a volumetric model in patients with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3542-3542

2016

Volltextzugriff (PDF)

SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3502-3502

2015

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(92)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(49)
Humans
(48)
Oncology
(41)
Female
(34)
Aged
(33)
Male
(33)
Middle Aged
(33)
Adult
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Tumors
(18)
Treatment Outcome
(17)
Aged, 80 And Over
(16)
Colorectal Neoplasms - Drug Therapy
(15)
Disease-Free Survival
(15)
Chemotherapy
(14)
Colorectal Cancer
(13)
Colorectal Neoplasms - Pathology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer―Results from NCIC CTG/AGITG CO.17

Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy

Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Reply to E.C. Harrold et al and A.O. Ayoola et al

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study

Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis

Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

A prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT in vitro diagnostic for the detection of biomarkers associated with colorectal cancer

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine―oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

Oxaliplatin‐induced interstitial lung disease

SIRFLOX study: Novel approach to define depth of response (DpR) within a volumetric model in patients with metastatic colorectal cancer (mCRC)

SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC)

Suchergebnisse filtern